In today’s session Juno Therapeutics Inc (JUNO) registered an unusually high (4,703) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious JUNO increase. With 4,703 contracts traded and 2704 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: JUNO161216C00035000 closed last at: $1.7 or 100% up. About 626,117 shares traded hands. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 23.49% since April 13, 2016 and is downtrending. It has underperformed by 27.41% the S&P500.
Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Juno Therapeutics Inc has been the topic of 18 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Neutral” rating given on Friday, July 8 by JP Morgan. The firm has “Buy” rating by Maxim Group given on Friday, August 5. The firm earned “Hold” rating on Thursday, October 29 by Standpoint Research. On Wednesday, July 6 the stock rating was initiated by Barclays Capital with “Equal-Weight”. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Outperform” rating given on Friday, July 8 by FBR Capital. As per Wednesday, November 18, the company rating was initiated by Goldman Sachs. As per Tuesday, August 18, the company rating was initiated by FBR Capital. The rating was initiated by Northland Capital with “Outperform” on Wednesday, July 22. The company was initiated on Thursday, February 25 by Citigroup. The company was upgraded on Tuesday, December 15 by Standpoint Research.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.34 in 2016 Q2. Its up 0.26, from 1.08 in 2016Q1. The ratio improved, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Moreover, Legal & General Group Public Ltd Company has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 5,470 shares. California Public Employees Retirement Systems, a California-based fund reported 79,500 shares. Vanguard Group owns 5.47M shares or 0.01% of their US portfolio. Schwab Charles Mngmt accumulated 234,448 shares or 0.01% of the stock. Profund Advisors Ltd Liability Company last reported 39,877 shares in the company. Pnc Fincl Svcs Group holds 800 shares or 0% of its portfolio. Moreover, First Republic Investment has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 5,935 shares. Baillie Gifford last reported 0.74% of its portfolio in the stock. Fred Alger Management Inc last reported 35,692 shares in the company. Royal Bankshares Of Canada reported 5,942 shares or 0% of all its holdings. Morgan Stanley accumulated 1.15 million shares or 0.02% of the stock. Moreover, Grp Inc One Trading Lp has 0.03% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 57,501 shares. Seven Eight Capital Limited Com has 1,001 shares for 0.01% of their US portfolio. Aqr Capital Mgmt Limited Company, a Connecticut-based fund reported 232,432 shares. Tekla Cap Management Lc has 182,000 shares for 0.29% of their US portfolio.
Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $3.51 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.
JUNO Company Profile
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
More recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” on November 03, 2016. Also Fool.com published the news titled: “Is Juno Therapeutics a Bargain or a Value Trap?” on November 07, 2016. Fool.com‘s news article titled: “Better Buy: Juno Therapeutics vs. Inovio Pharmaceuticals” with publication date: October 28, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.